Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Recruiting 3Completed 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Papillary renal cell carcinoma, sporadic 1Osteoradionecrosis 1Mouth Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Glioma 1Fallopian Tube Mucinous Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Contrast Media × 30 days × Clear all
NCT05937776 2026-06-05

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

OHSU Knight Cancer Institute

Completed
4 enrolled
CNS

Glioma

NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

NCT04265430 2026-05-22

Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors

M.D. Anderson Cancer Center

Phase 4 Recruiting
425 enrolled
Head & Neck

Mouth Neoplasms, Osteoradionecrosis

NCT03191149 2026-05-18

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

National Cancer Institute (NCI)

Phase 2 Recruiting
46 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡